Industry News

• Abbott statement: ACCORD lipid results support treatment guidelines for fibrate use  Results presented on behalf of the National Heart, Lung and Blood Institute from ACCORD, a study in patients with diabetes that evaluated cardiovascular outcomes in three distinct studies - glycemic control, blood pressure control and lipid control.
  Abbott March 14, 2010  
• Data demonstrates Abbott's MitraClip has potential to be a valuable treatment option  Data from the EVEREST II trial demonstrated that Abbott's investigational MitraClip® system met both its primary safety and effectiveness endpoints, suggesting the minimally invasive MitraClip procedure may be an important treatment option for patients with significant mitral regurgitation.
  Abbott March 14, 2010  
• FDA announces new boxed warning on Plavix  The U.S. Food and Drug Administration added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and health care professionals that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.
  FDA March 12, 2010  
• Sanofi-aventis and BMS announce important updates to PLAVIX U.S. prescribing info  Sanofi-aventis U.S. and Bristol-Myers Squibb announced revisions to the U.S. prescribing information for PLAVIX(R) (clopidogrel bisulfate), which include a boxed warning.
  Bristol-Myers Squibb Company March 12, 2010  
• Monsanto welcomes chance to participate in Dept. of Justice/Dept. of Agriculture workshop  As part of today's first joint public workshop exploring competition issues in the agriculture industry, Monsanto will participate in a panel discussion about the past, present and future of the seed and trait industry.
  Monsanto Company March 12, 2010  
• Oncothyreon consults with Division of Corporation Finance  Oncothyreon announced that it will restate its 2008 financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2008, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, June 30 and September 30, 2009 to correct a revenue recognition error.
  Oncothyreon, Inc. March 12, 2010  
• FDA's Black Box Warning addressed by Genelex's PlavitestT  The FDA added a new black box warning to Plavix, pointing out the importance of individual patient genetics in determining the effectiveness of Plavix treatment. The relabeling is in response to clinical research demonstrating that one-third of patients are in varying degrees of treatment failure.
  Genelex Corporation March 12, 2010  
• Pfizer discontinues a Phase 3 study of figitumumab  Pfizer announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced NSCLC.
  Pfizer Inc. March 11, 2010  
• Two Phase 3 trials of sunitinib did not meet the primary endpoint  Pfizer announced that two Phase 3 studies of Sutent(R) (sunitinib malate) in advanced breast cancer did not meet their primary endpoints.
  Pfizer Inc. March 11, 2010  
• Cardiac Science announces Q4 and full year 2009 results  Revenue for the fourth quarter of 2009 was $42.2 million, down 17% from the fourth quarter of 2008, but up 8% sequentially from the third quarter of 2009. Revenue for 2009 was $156.8 million, down 24% from 2008.
  Cardiac Science Corporation March 11, 2010  

   (next 10 articles)